Management of musculoskeletal complications of hemophilia.

Abstract:

:Prophylactic treatment from ages 2 to 18 years could prevent the development of hemophilic arthropathy if the concentration of the patient's deficient factor is kept from falling below 1% of normal. Early treatment is of paramount importance because the immature skeleton is very sensitive to the complications of hemophilia. Major hemarthrosis and chronic hemophilic synovitis should be treated aggressively to prevent hemophilic arthropathy. When advanced hemophilic arthropathy is present with severe disability, the aim should be to restore function while minimizing the risk to the patient. Joint debridement is an effective method to achieve this goal, especially around the elbow or ankle, and can be considered an alternative to knee replacement in the younger age groups. Proximal tibial valgus osteotomy is a reliable treatment method for painful genu varum of the mobile hemophilic knee. Supramalleolar tibial varus osteotomy is an attractive alternative to the more commonly used surgical option of arthrodesis. Finally, joint replacement can usually be relied on to restore both mobility and function in a diseased joint. The potential benefits of joint replacement must always be weighed against the long-term sequelae, however, especially loosening and consequent revision surgery.

journal_name

Semin Thromb Hemost

authors

Rodriguez-Merchan EC

doi

10.1055/s-2003-37942

subject

Has Abstract

pub_date

2003-02-01 00:00:00

pages

87-96

issue

1

eissn

0094-6176

issn

1098-9064

journal_volume

29

pub_type

杂志文章,评审
  • Thrombin Generation and Cirrhosis: State of the Art and Perspectives.

    abstract::Epidemiological and laboratory studies performed in the last decades have changed our understanding of coagulopathy in cirrhosis, from a condition at increased risk of hemorrhagic events to one at higher thrombotic risk. However, it is not clear whether the decrease in factors that promote (except factor [F] VIII) ver...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0040-1715102

    authors: Lebreton A,Sinegre T,Lecompte T,Talon L,Abergel A,Lisman T

    更新日期:2020-09-01 00:00:00

  • Bleeding Scores for the Diagnosis of von Willebrand Disease.

    abstract::Obtaining a personal history of bleeding is a critical component to the diagnosis of von Willebrand disease (VWD). The collection of this information can be challenging for physicians, however, as the reporting and interpretation of bleeding symptoms is subjective. The need for more precise quantification of bleeding ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1597289

    authors: Bowman ML,James PD

    更新日期:2017-07-01 00:00:00

  • Management of complications related to central venous catheters in cancer patients: an update.

    abstract::Central venous catheters (CVCs) are important for the treatment of patients with cancer, especially in the perioperative and palliative care settings. These devices not only allow for the administration of chemotherapy, parenteral nutrition, and other intravenous therapies, but they may also improve the patients' qual...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0034-1371005

    authors: Linnemann B

    更新日期:2014-04-01 00:00:00

  • Genetic Background of von Willebrand Disease: History, Current State, and Future Perspectives.

    abstract::Sequencing of the gene encoding for von Willebrand factor (VWF) has brought new insight into the physiology of VWF as well as its pathophysiology in the context of von Willebrand disease (VWD). Molecular testing in VWD patients has shown high variability in the overall genetic background of this condition. Almost 600 ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0039-3402430

    authors: Zolkova J,Sokol J,Simurda T,Vadelova L,Snahnicanova Z,Loderer D,Dobrotova M,Ivankova J,Skornova I,Lasabova Z,Kubisz P,Stasko J

    更新日期:2020-06-01 00:00:00

  • Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A.

    abstract::A simple nonisotopic method for the quantitation of FPA in biologic samples has been developed utilizing a competitive enzyme immunoassay technique. The performance characteristics of these assays have been investigated in both the experimental and clinical settings and were found to be satisfactory for the routine cl...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-1004428

    authors: Amiral J,Walenga JM,Fareed J

    更新日期:1984-10-01 00:00:00

  • The influence of beta2-glycoprotein I on tissue factor activity.

    abstract::The beta2-glycoprotein I (beta2-GPI) is known for its procoagulant as well as anticoagulant properties. The influence of beta2-GPI on tissue factor (TF) activity was investigated by chromogenic assays for both factor Xa generation and factor VIIa activity. When 1.36 mg/mL beta2-GPI was added to phospholipids prior to ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-995844

    authors: Ieko M,Yasukouchi T,Sawada KI,Koike T

    更新日期:1998-01-01 00:00:00

  • Management of venous thrombosis and pulmonary embolism after gynecological surgery.

    abstract::We experienced 23 cases of venous thrombosis after gynecological surgery for the past 12 years at Tokyo Women's Medical University Hospital, representing 0.345 % of all patients. Eighteen of the 23 cases had deep venous thrombosis (DVT) including five cases followed by pulmonary embolism (PE), and five cases had PE wi...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-996036

    authors: Adachi T,Nakabayashi M,Takeda Y

    更新日期:1998-01-01 00:00:00

  • Perturbation of protease inhibitors and substrates in inflammatory arthritis.

    abstract::Defective systemic fibrinolysis and articular persistence of fibrinlike material are well recognized in RA. Perturbation of the major plasma protease inhibitors, A1AT, A2MG, and AT III, was explored in RA, psoriatic arthritis, and Reiter's syndrome. Experimental evidence is presented and assessed with respect to the p...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-1004400

    authors: Rothschild BM,Thompson LD,Pifer DD,Chesney CM

    更新日期:1985-10-01 00:00:00

  • Hemostatic Efficacy of Pathogen-Inactivated Blood Components.

    abstract::Pathogen inactivation (PI), or pathogen reduction technology, reduces the infectious risk of plasma and platelet transfusions, and also affects clotting factor activities and platelet viabilities. Plasma is treated with solvent-detergent to disrupt enveloped viruses, or with photoactive agents methylene blue plus ligh...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0035-1564845

    authors: Ramsey G

    更新日期:2016-03-01 00:00:00

  • Circadian variation within hemostasis: an underrecognized link between biology and disease?

    abstract::Biological rhythms are a universal phenomenon in living organisms and serve to help organisms adapt within a circadian cycle to the 24-hour-oscillating environment. The rhythmic modulation of selective pathways thus enables organisms to optimize their ability to store and generate chemical energy, to minimize environm...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0029-1214145

    authors: Montagnana M,Salvagno GL,Lippi G

    更新日期:2009-02-01 00:00:00

  • Recombinant FVIIa in the treatment of warfarin bleeding.

    abstract::Patients receiving oral anticoagulant treatment have abnormally low levels of functional vitamin K-dependent coagulation proteins and consequently a clear risk of hemorrhagic complications. The incidence of hemorrhages has been reported to be around 0.6-0.7% per month at a therapeutic International Normalized Ratio (I...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2000-8464

    authors: Berntorp E

    更新日期:2000-01-01 00:00:00

  • Standardization of the INR: how good is your laboratory's INR and can it be improved?

    abstract::The prothrombin time (PT) assay is the most clinically ordered coagulation test and is most often used for monitoring of vitamin K antagonist (VKA) therapy (e.g., warfarin), where results are expressed as an international normalized ratio (INR). The INR is in essence the patient's PT "mathematically adjusted" to a sta...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0028-1104538

    authors: Favaloro EJ,Adcock DM

    更新日期:2008-10-01 00:00:00

  • Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma.

    abstract::The increase of circulating tissue factor pathway inhibitor (TFPI) in plasma by heparins is thought to contribute to their overall antithrombotic activity. In a clinical study in healthy volunteers, we recently found that the specific potency of a heparin to mobilize TFPI from the vessel wall increases with its molecu...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1055/s-2001-17952

    authors: Alban S

    更新日期:2001-10-01 00:00:00

  • To mix or not to mix in lupus anticoagulant testing? That is the question.

    abstract::Mixing patient and normal plasma has been used for many years to assist with making decisions on which direction to proceed for further investigation of abnormally prolonged coagulation tests, namely, either individual coagulation factor measurement or the search for circulating anticoagulants. Mixing tests, however, ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0032-1304717

    authors: Tripodi A

    更新日期:2012-06-01 00:00:00

  • Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.

    abstract::We investigated the protective effects of DX-9065a, an orally active, newly synthesized, and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation (DIC) in rats. Experimental DIC was induced by a 4 hour sustained infusion of thromboplastin at a dose of 2.5 mg/kg. The rats were or...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-999016

    authors: Yamazaki M,Asakura H,Aoshima K,Saito M,Jokaji H,Uotani C,Kumabashiri I,Morishita E,Ikeda T,Matsuda T

    更新日期:1996-01-01 00:00:00

  • Thrombin and antithrombotics.

    abstract::From injury through healing, thrombin has several important functions in blood clotting, subsequent clot lysis, and tissue repair. These include edema, inflammation, cell recruitment, cellular releases, transformations, mitogenesis, and angiogenesis. Thrombin also participates in disease states, such as venous thrombo...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-995828

    authors: Fenton JW 2nd,Ofosu FA,Brezniak DV,Hassouna HI

    更新日期:1998-01-01 00:00:00

  • Impact of automation on the quantitation of low molecular weight markers of hemostatic defects.

    abstract::Through in depth studies, the biochemical pathways of hemostasis-related systems have been elucidated in terms of well-defined molecular mechanisms. The interrelationships of coagulation, fibrinolytic, kallikrein-kinin, platelets, prostaglandins, blood vessel, and complement systems are now well understood. Methods ar...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:

    authors: Fareed J,Walenga JM,Bick RL,Bermes EJ Jr,Messmore HL Jr

    更新日期:1983-10-01 00:00:00

  • New-Onset Atrial Fibrillation and Adverse In-Hospital Outcome in Patients with Acute Pulmonary Embolism.

    abstract::Atrial fibrillation (AF) can be secondary to acute pulmonary embolism (PE). This study aimed to investigate the prognostic impact of new-onset AF on patients with acute PE. In this study, 4,288 consecutive patients who were diagnosed with acute PE were retrospectively screened. In total, 77 patients with acute PE and ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0040-1718397

    authors: Tang RB,Jing YY,Xu ZY,Dong JZ,Du X,Wu JH,Yu RH,Long DY,Ning M,Sang CH,Jiang CX,Bai R,Liu N,Wen SN,Li SN,Chen X,Huang ST,Cui YK,Ma CS

    更新日期:2020-11-01 00:00:00

  • Evaluation of hematologic alterations associated with daily administration of low molecular weight heparin (Mono-Embolex) for a 12-week period.

    abstract::The long-term success rate of coronary angioplasty is only 50 to 70% due to restenosis. The pathophysiologic mechanism of this event is mainly mediated by smooth muscle cell proliferation. To some extent, it can be inhibited by heparin. The introduction of LMWHs allows for prophylaxis against restenosis on an outpatie...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:

    authors: Lojewski B,Bacher P,Iqbal O,Walenga JM,Hoppensteadt DA,Leya F,Fareed J

    更新日期:1993-01-01 00:00:00

  • Prognostic Scores for Acute Pulmonary Embolism.

    abstract::Rapid and accurate risk stratification is critical in determining the optimal treatment strategy for patients with acute pulmonary embolism (PE). Early identification of patients with normal blood pressure and a favorable prognosis (low-risk PE) might select a subset of patients for outpatient treatment, which is asso...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1597287

    authors: Morillo R,Moores L,Jiménez D

    更新日期:2017-07-01 00:00:00

  • Angiostatin.

    abstract::The quiescent vascular system in the adult body represents the imbalanced net outcome of overproduction of endogenous angiogenesis inhibitors and reduced levels of angiogenic factors. While some endogenous inhibitors are expressed under physiological conditions, they can also be generated in association with tumor gro...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2004-822973

    authors: Cao Y,Xue L

    更新日期:2004-02-01 00:00:00

  • Emerging issues on comprehensive hemophilia care: preventing, identifying, and monitoring age-related comorbidities.

    abstract::Life expectancy for persons with hemophilia (PWH) has considerably increased in the last decades as a direct result of the availability of modern therapies to control the clotting defect. Because their life expectancy now matches that of the general population, PWH are experiencing age-related comorbidities, such as, ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0033-1354424

    authors: Coppola A,Santoro C,Franchini M,Mannucci C,Mogavero S,Molinari AC,Schinco P,Tagliaferri A,Santoro RC

    更新日期:2013-10-01 00:00:00

  • Management of oral anticoagulant treatment in patients with venous thromboembolism.

    abstract::Oral anticoagulants (OAs) are the drugs of choice for the prevention of recurrence and death in patients with venous thromboembolism (VTE). Oral anticoagulant treatment (OAT) aims to retard blood coagulation to obtain maximum protection against thromboembolic events with the lowest risk of bleeding. The intensity of O...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2006-955460

    authors: Pengo V

    更新日期:2006-11-01 00:00:00

  • Fibrin D-dimer in thrombogenic disorders.

    abstract::Measurement of D-dimer (fibrin degradation product) is important for determining not only the activation of fibrinolysis but also the severity of a hypercoagulable state. However, fibrin degradation products are in variable, and the reactivity to cross-linked fibrin degradation products produced during fibrin degradat...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2000-9811

    authors: Matsuo T,Kobayashi H,Kario K,Suzuki S

    更新日期:2000-01-01 00:00:00

  • Hemophilia orthopedic management with emphasis on developing countries.

    abstract::The articular problems of patients with hemophilia begin in infancy when minor injuries result in hemarthroses. Early continuous prophylaxis (from cradle to college) is of paramount importance because the immature skeleton is very sensitive to the complications of hemophilia; severe structural deficiencies may develop...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2005-922223

    authors: Rodriguez-Merchan EC,Heim M

    更新日期:2005-11-01 00:00:00

  • Management of Coagulopathy in Postpartum Hemorrhage.

    abstract::The purpose of this article is to review the use of blood products and hemostatic agents in the management of coagulopathy at the time of postpartum hemorrhage. Blood product administration strategies are broadly reviewed, including the role of the blood bank, the role of massive transfusion protocols, the role of lab...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1593417

    authors: James AH,Grotegut C,Ahmadzia H,Peterson-Layne C,Lockhart E

    更新日期:2016-10-01 00:00:00

  • How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice?

    abstract::Fibrin formed from fibrinogen is the main component of thrombi. Clot structure is characterized by fiber thickness and pore size, which differs within a given clot and between individuals. Plasma clot architecture is largely determined by the quantity and quality of fibrinogen. Plasma fibrinogen concentrations are mos...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1579636

    authors: Undas A

    更新日期:2016-06-01 00:00:00

  • Recombinant peptides in thrombolysis.

    abstract::Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are altepl...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0030-1255447

    authors: Campbell J,Hilleman D

    更新日期:2010-07-01 00:00:00

  • NETosis: a new factor in tumor progression and cancer-associated thrombosis.

    abstract::Neutrophils have long been known as innate immune cells that phagocytose and kill pathogens and mount inflammatory responses protecting the host from infection. In the past decades, new aspects of neutrophils have emerged unmasking their importance not only in inflammation but also in many pathological conditions incl...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0034-1370765

    authors: Demers M,Wagner DD

    更新日期:2014-04-01 00:00:00

  • Metabolic modulation of inflammation-induced activation of coagulation.

    abstract::The bidirectional interaction between coagulation and inflammation, which is relevant in various disease states that are dominated by systemic inflammatory responses, such as severe infection or chronic vascular disease, is modulated by metabolic factors. Changes in lipoprotein metabolism affect the inflammation-induc...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2008-1066020

    authors: Levi M,Nieuwdorp M,van der Poll T,Stroes E

    更新日期:2008-02-01 00:00:00